Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
glucose clamp · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Hypoglycaemia / euglycaemia clamp | OTHER | - |
| Euglycaemia clamp / hypoglycaemia | OTHER | - |
| Normoglycaemia followed by hypoglycaemia | OTHER | - |
| Hypoglycaemia followed by normoglycaemia | OTHER | - |
| Name | Type | Description |
|---|---|---|
| glucose clamp | OTHER | Each subject will be randomly allocated to an experimental visit sequence consisting of a hypoglycaemic glucose clamp followed by euglycaemic glucose clamp (using i.v. infusion of human soluble insulin (Actrapid®)) or vice versa separated by at least 21 days. Each visit includes an overnight stay. For each of the two conditions (euglycaemia and hypoglycaemia) cognitive performance will be assessed by a validated cognitive test |
Inclusion Criteria: * Right-handed subjects * Type 1 diabetes mellitus for at least 12 months * Treated with multiple daily insulin injections or continuous subcutaneous insulin infusion (CSII) for at least 12 months * Body mass index 18.0-28.0 kg/m\^2 (both inclusive) Exclusion Criteria: * Subje...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
Glucose clamp is an investigational tool being studied in diabetes. It is used in clinical trials to investigate the impact of hypoglycemia on sleep and cognitive function in people with type 1 and type 2 diabetes. It is currently in Phase 1 clinical development.
Glucose clamp is being developed by Novo Nordisk A/S, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVO. The company is conducting Phase 1 clinical trials to evaluate the effects of hypoglycemia in patients with diabetes.
Glucose clamp is in Phase 1 clinical development. Two Phase 1 trials have been completed, with a total of 55 participants enrolled. The drug is investigational and has not been approved by regulatory authorities for commercial use.
Glucose clamp has been studied in two completed Phase 1 trials. NCT01780272 investigated the impact of nocturnal hypoglycemia on sleep in 26 subjects with type 2 diabetes. NCT01789593 investigated the effect of acute hypoglycemia on cognitive function and brain activation in 29 subjects with type 1 diabetes.
Glucose clamp is not the same as insulin. It is an investigational tool used in clinical trials to study the effects of hypoglycemia in patients with diabetes. It is being developed by Novo Nordisk, a company known for insulin products, but glucose clamp itself is not an insulin product.